+91-8668442535

Continuous Glucose Monitoring Devices Market By Component (Sensors, Transmitters & Receivers and Insulin Pumps), By Application (Diabetic Patients and Healthy Individuals) - Growth, Future Prospects, and Competitive Analysis, 2017 -2025

Continuous glucose monitoring (CGM) devices are the latest advancement in the market for diabetes monitoring devices, in which a sensor is linked to the CGM device and placed on the patient’s skin. The device measures glucose levels in the interstitial fluid at frequent intervals and provides data that is captured via a transmitter and sent to the receiver. These newer devices are projected to show positive market growth in the forecast period, 2017-2025, owing to the presence of factors such as an increasing diabetic population and a rise in technological development focusing on smart connectivity options, thus providing remote monitoring by the physicians, rising demand for patient-specific treatment approaches, and a continuously developing reimbursement scenario.

The current report provides analytical insights and a complete understanding of the present and upcoming CGM device market scenario. It includes a market analysis and forecast for 2015-2025. Furthermore, a complete dissected evaluation of the CGM devices market by segmenting the market based on components, applications, and diverse geographies has been incorporated.

The global market for CGM devices is bifurcated based on the components of the device and its application. The components are sub-segmented into sensors, transmitters and receivers, and insulin pumps. CGM devices are predominantly used by diabetic patients, and their use in healthy individuals has currently begun as a preventive care option. The application is thus sub-segmented into diabetic patients and healthy individuals.

The market estimation and forecast analysis for the aforementioned segments are provided for the time period of 2015-2025 and are valued in US dollars million. Furthermore, the respective compound annual growth rates (CAGRs) for each of the segments have been included for the time scale 2017-2025, with 2016 as the base year.

The CGM devices market is also evaluated based on various geographies, viz., North America, Europe, Asia Pacific, Latin America & the Middle East, and Africa. These geographical regions are further subdivided into the United States, Canada, the United Kingdom, Germany, China, Japan, Brazil, Mexico, Saudi Arabia, and South Africa. Market estimation and forecast analysis for the above-mentioned geographies for the period 2015–2025 and respective growth rates for the duration 2017–2025 have been included in the current report.

The CGM devices market is dominated by several large and medium-sized companies, rendering this market highly competitive. There is a significant opportunity for newer key players with advanced and developed glucose monitoring devices that require little invasion. The key industries in the CGM devices market are Abbott Laboratories, Echo Therapeutics, Inc., Dexcom, Inc., GlySens Incorporated, Medtronic plc, Senseonics Holdings, Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AgaMatrix, Inc., Glucovation, GlySure, Arkray USA, Inc., Orense, Tandem Diabetes Care, and Pinnacle Technology.

Based on applications, the global market for continuous glucose monitoring devices is segmented as follows:

Diabetic Patients

  • Type 1 diabetes
  • Type 2 diabetes

Healthy Individuals

Continuous glucose monitoring (CGM) devices allow for continuous monitoring of blood glucose levels as well as trend analysis, resulting in patient-centered care.CGM devices are primarily utilized by diabetic populations to monitor blood glucose levels, thus capturing a major market share in the overall diabetes care market. Healthy individuals have recently begun to use CGM devices to enhance lifestyle patterns and monitor sugar levels as preventive care, seizing a smaller market share. Type 1 diabetes is an autoimmune condition where external insulin is required to maintain the glucose level, whereas, in type 2 diabetes, the body is resistant to insulin, thus leading to high glucose levels. This condition is maintained by oral medications and, in very rare cases, requires insulin therapy. The need for continuous sugar monitoring in order to inject an appropriate dose of insulin in type 1 diabetes patients is a major factor in this segment, capturing a larger market share.

Based on components, the global market for continuous glucose monitoring devices is segmented as follows:

  • Sensors
  • Transmitters and Receivers
  • Insulin Pumps

Continuous glucose monitoring (CGM) devices allow for continuous mapping of blood glucose levels as well as trend analysis, facilitating patient-centered care. For the purpose of this study, the global CGM devices market is segmented based on the components utilized, viz., sensors, transmitters and receivers, and insulin pumps. Among the aforementioned components, transmitters and receivers predominated the CGM devices market in the base year of 2016, owing to their higher costs. However, this trend is expected to change in the forecast period, where insulin pumps will have a higher contribution to the CGM devices market as new technological developments have begun to fuse insulin pumps with CGM technology. Sensors are a constitutive part of the CGM system, where their sensitivity is essential to acquiring accurate glucose levels in the interstitial fluids and thus needs to be replaced periodically to maintain accuracy. The contribution of the sensor segment is also projected to rise at a higher growth rate in the forecast period, owing to the development of more sensitive technologies and a rise in demand for CGM devices.

For the purpose of this study, the global continuous glucose monitoring devices market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Among the considered geographies, North America, followed by Europe, accounts for the major share in the continuous glucose monitoring devices market due to the rise in developed healthcare infrastructure with improving reimbursement policies, the drive towards attaining a patient-centric healthcare approach, and technological advancements in healthcare monitoring. The approval of Abbott’s FreeStyle Libre device, Dexcom’s G4 and G5, and Medtronic’s Enlite and Enlite 2 in North America and Europe will propel the growth of the continuous glucose monitoring devices market in these regions. The rising prevalence of diabetes in emerging economies such as India, China, Latin America, the Middle East, and Africa is expected to fuel the global growth of the CGM devices market. However, the high pricing of CGM devices, discomfort observed among patients using CGM devices, and the insufficient existence of healthcare IT products and services may have a negative impact on the CGM device market in developing economies.

Frequently Asked Question:

The market for Continuous Glucose Monitoring Devices Market is expected to reach USD$ 1.3 Bn in 2025.

The Continuous Glucose Monitoring Devices Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted to 2017-2025.

The base year of this report is 2016.

Abbott Laboratories, Echo Therapeutics, Inc., Dexcom, Inc., GlySens Incorporated, Medtronic plc, Senseonics Holdings, Inc., Johnson & Johnson. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Nov 2017
Category:  Medical Devices
Report ID:   58813
Report Format:   PDF
Pages:   120
Rating:    4.7 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support